Core Concepts
Penbraya, a new pentavalent meningococcal vaccine, has been approved by the FDA for individuals aged 10-25, offering broad protection against the five most common serogroups causing the disease.
Abstract
The FDA has approved Penbraya, a new meningococcal vaccine by Pfizer, which combines components from two existing vaccines. This pentavalent vaccine targets the five most common serogroups causing the disease and is specifically approved for individuals aged 10-25. The vaccine aims to provide broader coverage in fewer shots, potentially increasing vaccination rates among adolescents and young adults. Meningococcal disease, although rare, can be severe and life-threatening, emphasizing the importance of effective prevention strategies. The FDA's decision was based on positive results from phase 2 and phase 3 trials, with the CDC Advisory Committee on Immunization Practices set to discuss recommendations for Penbraya's use in young people.
Stats
The FDA approved a new meningococcal vaccine against the five most common serogroups causing disease in children and young adults.
Penbraya is the first pentavalent vaccine for meningococcal disease and is approved for use in people aged 10-25.
The phase 3 trial for Penbraya included more than 2400 patients from the US and Europe.
Quotes
"Today marks an important step forward in the prevention of meningococcal disease in the US." - Annaliesa Anderson, PhD